2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:

Please note – the press team can only answer enquiries from accredited members of the press.
Related articles

Smiths Group plc – Q3 Trading Update
Find out more
Smiths Detection awarded contract to provide checkpoint screening technology for Dubai International Airport
Read our latest company news as Smiths Detection is awarded a new contract from DAEP to provide checkpoint screening technology for Dubai International Airport
Find out more![Davinci Gen V Gen Front View[36]](/media/wlocq5n4/davinci-gen-v-gen-front-view-36.jpg?width=431&height=214&format=webp&quality=100&v=1dbb81c2473de50)
Smiths Interconnect launches ‘DaVinci Gen V’ next-generation test socket
Read our latest company news as Smiths Interconnect launches ‘DaVinci Gen V’ next-generation test socket
Find out more